Clinical impact of dyspnoea after ticagrelor treatment and the effect of switching to clopidogrel in patients with myocardial infarction

CONCLUSIONS: Dyspnoea is a common side effect among ticagrelor-based DAPT in AMI patients. Switching from ticagrelor to clopidogrel after 1 month in AMI patients may provide a reasonable option to alleviate subsequent dyspnoea in ticagrelor-relevant dyspnoeic patients, without increasing the risk of ischaemic events (NCT02018055).PMID:38574757 | DOI:10.1055/a-2299-4537

Source: Thrombosis and Haemostasis - April 4, 2024 Category: Hematology Authors: Sang Hyun Kim Sanghoon Shin Eun Ho Choo Ik Jun Choi Sungmin Lim Donggyu Moon Chan Joon Kim Mahn-Won Park Min Chul Kim Byung-Hee Hwang Kwan Yong Lee Yun-Seok Choi Hee-Yeol Kim Ki-Dong Yoo Doo Soo Jeon Youngkeun Ahn Kiyuk Chang Source Type: research